2024年12月30日 · AXS-05 is a fixed-dose combination of two approved drugs being developed for the treatment of agitation in people with Alzheimer’s disease. One component, dextromethorphan, is the active ingredient in several brands of cough syrup.

Tools Ward K, Citrome L . AXS-05: an investigational treatment for Alzheimer's disease-associated agitation . Expert Opin Investig Drugs. 2022 Aug;31 (8):773-780. Epub 2022 Jul 6 PubMed .

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) . J Clin Psychiatry. 2022 May 30;83 (4) PubMed .

2023年5月22日 · Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 Jul;179 (7):490-499.

alpha-synuclein Amyloid-Related Cholesterol Cholinergic System Inflammation Metals Other Other Neurotransmitters Tau Unknown

Target Type All alpha-synuclein Amyloid-Related Cholesterol Cholinergic System Inflammation Metals Other Other Neurotransmitters Tau Unknown

2015年11月25日 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 ACI-3024 ACI-35 ACI-7104.056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AKST4290 AL002 AL003 AL044 AL101 Allopregnanolone ALN-APP ALPHA-1062 Alpha-Tocopherol ALX ...

Other compounds with sigma1R agonist activity are in clinical trials for Alzheimer's disease; they include blarcamesine, edonerpic, and the dextromethorphan formulations AVP-786, AVP-923, and AXS-05.

2024年5月22日 · Overview Name: AVP-786 Therapy Type: Combination, Small Molecule (timeline) Target Type: Other Neurotransmitters (timeline) Condition (s): Alzheimer's Disease, Schizophrenia U.S. FDA Status: Alzheimer's Disease (Discontinued), Schizophrenia (Discontinued) Company: Avanir Pharmaceuticals, Concert Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd. Background This investigational therapeutic ...